Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study

Table 3 ICU complications during stay

Outcomes	Number of outcomes/Total number of patients		P-value	Odds Ratio (OR) (95%CI)	P-value $
Outcomes	DEX (n = 75)	mPRED (n = 30)	P-value	Odds Ratio (OR) (95%CI)	P-value $
Respiratory failure requiring MV, n (%)^b	1 ( 20.0)	1 ( 25.0)	0.86**	1.24 (0.06,26.78)	0.89
Acute kidney injury, n(%)^a	6 ( 25.0)	7 ( 29.2)	0.75^^	1.36 (0.37,4.94)	0.65
Liver injury, n(%)^a	2 ( 8.3)	1 ( 4.2)	0.55**	0.52 (0.04,6.24)	0.61
Hospital acquired infection, n(%)^a	3 ( 12.5)	6 ( 25.0)	0.27**	2.38 (0.54,10.53)	0.25

DEX Dexamethasone, mPRED Methylprednisolone
^aDenominator of the percentage is the total number of patients
^bDenominator of the percentage is the non-MV patients
^^Chi-square test is used to calculate the P-value/** Fisher’s Exact teat is used to calculate P-value
^$*Logistic regression is used to calculate the OR and p-value

ISSN: 1471-2466